Home › Companies › RECURSION PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore RECURSION PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Blake Borgeson, Ph.D. | 165,914,956 | -- | -- | 26,093,759 | 0 | Majority: yes |
| Elect Director: Dean Y. Li, M.D., Ph.D. | 166,211,058 | -- | -- | 25,797,657 | 0 | Majority: yes |
| Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: | 188,317,831 | 2,887,180 | 803,704 | -- | 0 | Majority: yes |
Source: RECURSION PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.
Each item below shows how the 227 asset managers that disclosed a RECURSION PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RECURSION PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”): 188,317,831 for, 2,887,180 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 237,508,682 outstanding shares: 79% for, 1% against (81% of the company cast a for/against vote).
The 220 asset managers below cast 97% of the shares they voted on this item FOR (63,777,075 for, 1,973,482 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO LTD | 18,866,091 | 0 | 0 | 0 | For |
| Nikko Asset Management Americas, Inc. | 8,909,455 | 0 | 0 | 0 | For |
| Vanguard | 8,108,402 | 0 | 0 | 0 | For |
| State Street | 2,949,639 | 0 | 0 | 0 | For |
| BlackRock | 2,749,242 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 2,591,820 | 0 | 0 | 0 | For |
| Charles Schwab | 2,428,434 | 0 | 0 | 0 | For |
| Lingotto Investment Management LLP | 2,175,077 | 0 | 0 | 0 | For |
| UBS | 0 | 1,618,914 | 0 | 0 | Against |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,570,614 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 1,403,642 | 0 | 0 | 0 | For |
| MIC Capital Management UK LLP | 1,388,889 | 0 | 0 | 0 | For |
| Liontrust Investment Partners LLP | 872,449 | 0 | 0 | 0 | For |
| Northern Trust | 745,518 | 93 | 0 | 0 | For |
| Vestmark Advisory Solutions, Inc. | 728,095 | 0 | 0 | 0 | For |
| Cercano Management LLC | 685,018 | 0 | 0 | 0 | For |
| Fidelity | 593,852 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 398,936 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 393,174 | 0 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 393,174 | 0 | 0 | 0 | For |
| Lazard | 373,163 | 0 | 0 | 0 | For |
| Sculptor Capital II LP | 318,400 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 292,812 | 0 | 0 | 0 | For |
| Mitsubishi UFJ Trust & Banking Corp | 270,360 | 0 | 0 | 0 | For |
| Morgan Stanley | 267,862 | 0 | 0 | 0 | For |
Showing the 25 largest of 220 asset managers. See all 220 in the interactive database.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Blake Borgeson, Ph.D.”): 165,914,956 for, 26,093,759 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 237,508,682 outstanding shares: 70% for, 11% withheld (81% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (8,788,626 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,991,528 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,214,217 | 0 | Abstain |
| BlackRock | 0 | 0 | 1,172,703 | 0 | Abstain |
| State Street | 837 | 0 | 785,461 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 393,174 | 0 | Abstain |
| Fidelity | 150,174 | 0 | 78,632 | 0 | For |
| Lincoln Financial | 57,413 | 0 | 129,273 | 0 | Abstain |
| Nushares ETF Trust | 181,145 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 157,852 | 0 | Abstain |
| ProShares | 0 | 0 | 148,460 | 0 | Abstain |
| WisdomTree | 129,041 | 0 | 0 | 0 | For |
| JPMorgan | 128,515 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 118,227 | 0 | Abstain |
| Dimensional | 0 | 0 | 99,793 | 0 | Abstain |
| First Trust | 0 | 0 | 95,521 | 0 | Abstain |
| Morgan Stanley | 0 | 0 | 79,722 | 0 | Abstain |
| Global X | 0 | 0 | 66,042 | 0 | Abstain |
| WESMARK FUNDS | 0 | 0 | 65,200 | 0 | Abstain |
| Northern Trust | 0 | 0 | 59,285 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| Pacific Life | 0 | 0 | 55,774 | 0 | Abstain |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dean Y. Li, M.D., Ph.D.”): 166,211,058 for, 25,797,657 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 237,508,682 outstanding shares: 70% for, 11% withheld (81% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (8,879,763 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,991,528 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,214,217 | 0 | Abstain |
| BlackRock | 0 | 0 | 1,172,703 | 0 | Abstain |
| State Street | 837 | 0 | 785,461 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 393,174 | 0 | Abstain |
| Fidelity | 150,174 | 0 | 78,632 | 0 | For |
| Lincoln Financial | 57,413 | 0 | 129,273 | 0 | Abstain |
| Nushares ETF Trust | 181,145 | 0 | 0 | 0 | For |
| Equitable | 3,507 | 0 | 154,345 | 0 | Abstain |
| ProShares | 0 | 0 | 148,460 | 0 | Abstain |
| WisdomTree | 129,041 | 0 | 0 | 0 | For |
| JPMorgan | 128,515 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 118,227 | 0 | Abstain |
| Dimensional | 0 | 0 | 99,793 | 0 | Abstain |
| First Trust | 0 | 0 | 95,521 | 0 | Abstain |
| Morgan Stanley | 74,685 | 0 | 5,037 | 0 | For |
| Global X | 0 | 0 | 66,042 | 0 | Abstain |
| WESMARK FUNDS | 0 | 0 | 65,200 | 0 | Abstain |
| Northern Trust | 0 | 0 | 59,285 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| Pacific Life | 0 | 0 | 55,774 | 0 | Abstain |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
100% fund support · no official result
The 20 asset managers below cast 100% of the shares they voted on this item FOR (2,623,747 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,484,830 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,214,217 | 0 | Abstain |
| JPMorgan | 0 | 0 | 128,515 | 0 | Abstain |
| Global X | 0 | 0 | 66,042 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 57,413 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
| AMERICAN BEACON FUNDS | 24,998 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 20,700 | 0 | 0 | 0 | For |
| NEW COVENANT FUNDS | 0 | 0 | 11,559 | 0 | Abstain |
| Allianz | 0 | 0 | 4,160 | 0 | Abstain |
| Russell Investments | 0 | 0 | 1,274 | 0 | Abstain |
| Nationwide | 0 | 0 | 1,150 | 0 | Abstain |
| SEI | 0 | 0 | 600 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 473 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 424 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 0 | 0 | 10 | 0 | Abstain |
— fund support · no official result
No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lincoln Financial | 0 | 0 | 0 | 0 | Not Voted |
| Humankind Benefit Corp | 0 | 0 | 0 | 0 | Unknown |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | Non-Voting Ballot |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 0 | -- |
98% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”): 188,317,831 for, 2,887,180 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 237,508,682 outstanding shares: 79% for, 1% against (81% of the company cast a for/against vote).
The 3 asset managers below cast 99.5% of the shares they voted on this item FOR (406,717 for, 1,747 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 406,617 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 1,747 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 100 | 0 | 0 | 0 | For |
Ranked by the number of RECURSION PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 237,508,682 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAILLIE GIFFORD & CO LTD | 7.94% |
| 2 | Nikko Asset Management Americas, Inc. | 3.75% |
| 3 | Vanguard | 3.41% |
| 4 | State Street | 1.24% |
| 5 | BlackRock | 1.16% |
| 6 | BAILLIE GIFFORD OVERSEAS LTD | 1.09% |
| 7 | Charles Schwab | 1.02% |
| 8 | Lingotto Investment Management LLP | 0.92% |
| 9 | UBS | 0.68% |
| 10 | PLATINUM INVESTMENT MANAGEMENT LTD | 0.66% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 16.75% | 13F |
| BlackRock | 13.36% | 13F |
| Baillie Gifford & Co | 10.18% | DEF14A |
| ARK Investment Management LLC | 9.72% | 13G |
| MDC Capital Partners | 8.44% | DEF14A |
| Zachary Bogue | 5.74% | DEF14A |
| DCVC | 5.73% | DEF14A |
| FMR LLC | 4.59% | DEF14A |
| Kinnevik AB | 4.38% | DEF14A |
| State Street | 4.36% | 13F |
Percentages above are of 237,508,682 shares outstanding, as reported by RECURSION PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At RECURSION PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-03, in the 2023-2024 proxy season, 227 asset managers reported how they voted in their SEC Form N-PX filings, covering 870 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2024 PROXY STATEMENT. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RECURSION PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.
RECURSION PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.